$2.96
8.64% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Zentalis Pharmaceuticals Inc Target price 2024 - Analyst rating & recommendation

Zentalis Pharmaceuticals Inc Classifications & Recommendation:

Buy
36%
Hold
64%

Zentalis Pharmaceuticals Inc Price Target

Target Price $9.90
Price $2.96
Potential
Number of Estimates 10
10 Analysts have issued a price target Zentalis Pharmaceuticals Inc 2025 . The average Zentalis Pharmaceuticals Inc target price is $9.90. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 4 Analysts recommend Zentalis Pharmaceuticals Inc to buy, 7 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Zentalis Pharmaceuticals Inc stock has an average upside potential 2025 of . Most analysts recommend the Zentalis Pharmaceuticals Inc stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 40.62

11 Analysts have issued a sales forecast Zentalis Pharmaceuticals Inc 2024 . The average Zentalis Pharmaceuticals Inc sales estimate is

$40.6m
Unlock
. This is
0.14% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$41.0m 1.08%
Unlock
, the lowest is
$40.6m 0.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$0.0 100.00%
Unlock
2027
$42.8m 85.81%
Unlock
2028
$175m 310.03%
Unlock

2 Analysts have issued an Zentalis Pharmaceuticals Inc EBITDA forecast 2024. The average Zentalis Pharmaceuticals Inc EBITDA estimate is

$-226m
Unlock
. This is
3.20% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-224m 2.01%
Unlock
, the lowest is
$-229m 4.39%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-253m 11.82%
2024
$-226m 10.42%
Unlock
2025
$-277m 22.31%
Unlock
2026
$-287m 3.73%
Unlock

EBITDA Margin

11 Zentalis Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Zentalis Pharmaceuticals Inc net profit estimate is

$-206m
Unlock
. This is
5.36% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-174m 11.27%
Unlock
, the lowest is
$-224m 14.55%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-318m 0.22%
2024
$-206m 35.18%
Unlock
2025
$-253m 22.89%
Unlock
2026
$-236m 6.89%
Unlock
2027
$-212m 10.26%
Unlock
2028
$-119m 43.80%
Unlock

Net Margin

2027
-494.70% 51.70%
Unlock
2028
-67.81% 86.29%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -4.47 -2.90
0.22% 35.12%
P/E negative
EV/Sales negative

11 Analysts have issued a Zentalis Pharmaceuticals Inc forecast for earnings per share. The average Zentalis Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.90
Unlock
. This is
5.45% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.44 11.27%
Unlock
, the lowest is
$-3.15 14.55%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-4.47 0.22%
2024
$-2.90 35.12%
Unlock
2025
$-3.56 22.76%
Unlock
2026
$-3.31 7.02%
Unlock
2027
$-2.98 9.97%
Unlock
2028
$-1.67 43.96%
Unlock

P/E ratio

Current -1.08 70.97%
2024
-1.02 5.56%
Unlock
2025
-0.83 18.63%
Unlock
2026
-0.89 7.23%
Unlock
2027
-0.99 11.24%
Unlock
2028
-1.77 78.79%
Unlock

Based on analysts' sales estimates for 2024, the Zentalis Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-4.23
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -4.24
2024
-4.23 0.20%
Unlock
2027
-4.02 46.18%
Unlock
2028
-0.98 75.61%
Unlock

P/S ratio

Current
2024
5.18 0.14%
Unlock
2027
4.92 46.18%
Unlock
2028
1.20 75.61%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today